Adalimumab
Treatment De-Escalation in Rheumatoid Arthritis
Patients with rheumatoid arthritis who are in sustained remission or low disease activity after treatment with tumor necrosis factor inhibitors (TNFi) may be good candidates for treatment de-escalation, according to a new study. Research conducted by a team from Loma Linda University found that discontinuing maintenance TNFi treatment resulted in